Japan Lifeline Management

Management criteria checks 2/4

Japan Lifeline's CEO is Keisuke Suzuki, appointed in Jun 2005, has a tenure of 18.92 years. directly owns 14.93% of the company’s shares, worth ¥12.96B. The average tenure of the management team and the board of directors is 4.9 years and 5.9 years respectively.

Key information

Keisuke Suzuki

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	18.9yrs
CEO ownership	14.9%
Management average tenure	4.9yrs
Board average tenure	5.9yrs

Recent management updates

Recent updates

Japan Lifeline (TSE:7575) Is Increasing Its Dividend To ¥42.00

Mar 02

CEO

Keisuke Suzuki (70 yo)

18.9yrs

Tenure

Mr. Keisuke Suzuki has been the President of Japan Lifeline Co., Ltd. since June 2005 and serves as its Chief Executive Officer. Mr. Suzuki served as Vice President of Japan Lifeline Co., Ltd., since April...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Keisuke Suzuki	President	18.9yrs	no data	14.93% ¥ 13.0b
Atsuhiro Suzuki	Senior Executive Vice President & COO	no data	no data	0.48% ¥ 413.5m
Kenji Yamada	Senior VP	no data	no data	0.035% ¥ 30.1m
Yumiko Hoshiba	VP, GM of Human Resources & General Affairs Department and Director	1.9yrs	no data	0.019% ¥ 16.2m
Takayuki Kuronuma	Consultant	4.9yrs	no data	no data
Toru Takamiya	VP, Executive Manager of R&D and Manufacturing Headquarters & Director	6.9yrs	no data	0.0040% ¥ 3.5m
Tadashi Idei	VP, Exec. Manager of Regulatory Affairs HQ	6.9yrs	no data	0.0053% ¥ 4.6m
Tatsuya Murase	SVP, Executive Manager of General Business Headquarters & CVG Business Unit and Director	3.8yrs	no data	0.0013% ¥ 1.2m
Shigeki Kitayama	Operating Officer & Senior Manager of EP Department of Arrhythmia Business Unit	no data	no data	no data
Naohiro Nakada	Operating Officer	no data	no data	no data
Takahiko Suzuki	Operating Officer	no data	no data	no data
Takeyoshi Egawa	VP, Sr, Manager of Buss. Admin. Dept of Corp Admin HQ.	less than a year	no data	no data

4.9yrs

Average Tenure

59yo

Average Age

Experienced Management: 7575's management team is considered experienced (4.9 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Keisuke Suzuki	President	18.9yrs	no data	14.93% ¥ 13.0b
Kenji Yamada	Senior VP	no data	no data	0.035% ¥ 30.1m
Yumiko Hoshiba	VP, GM of Human Resources & General Affairs Department and Director	5.9yrs	no data	0.019% ¥ 16.2m
Toru Takamiya	VP, Executive Manager of R&D and Manufacturing Headquarters & Director	6.9yrs	no data	0.0040% ¥ 3.5m
Tadashi Idei	VP, Exec. Manager of Regulatory Affairs HQ	6.9yrs	no data	0.0053% ¥ 4.6m
Tatsuya Murase	SVP, Executive Manager of General Business Headquarters & CVG Business Unit and Director	1.9yrs	no data	0.0013% ¥ 1.2m
Takeyoshi Egawa	VP, Sr, Manager of Buss. Admin. Dept of Corp Admin HQ.	less than a year	no data	no data
Fumihiro Sasaki	Independent Outside Director	11.9yrs	no data	0.0040% ¥ 3.5m
Yoshiaki Ikei	Independent Outside Director	6.9yrs	no data	0.0040% ¥ 3.5m
Yutaka Karigome	Independent Outside Director	2.9yrs	no data	no data
Masahiko Nakamura	Outside Independent Director	2.9yrs	no data	no data
Daizo Asari	Independent Outside Director	2.9yrs	no data	0.0040% ¥ 3.5m

5.9yrs

Average Tenure

59.5yo

Average Age

Experienced Board: 7575's board of directors are considered experienced (5.9 years average tenure).

Japan Lifeline Management

Management criteria checks 2/4

Key information

Recent management updates

Japan Lifeline Co., Ltd., Annual General Meeting, Jun 26, 2024

Japan Lifeline Co., Ltd. Announces the Appointment of Nobuo Takahashi as Operating Officer, Associate Executive Manager of CVG Business Unit

Japan Lifeline Co., Ltd. Announces Management Changes

Japan Lifeline Co., Ltd., Annual General Meeting, Jun 28, 2023

Japan Lifeline Announces Changes in Board of Directors, Effective June 28, 2023

Japan Lifeline Co., Ltd. Announces Executive Changes, Effective October 1, 2022 Respectively

Recent updates

Japan Lifeline Co., Ltd., Annual General Meeting, Jun 26, 2024

Upcoming dividend of JP¥42.00 per share

Japan Lifeline (TSE:7575) Is Increasing Its Dividend To ¥42.00

Japan Lifeline Co., Ltd. to Report Q4, 2024 Results on May 01, 2024

Price target increased by 11% to JP¥1,400

Third quarter 2024 earnings released: EPS: JP¥28.32 (vs JP¥11.15 in 3Q 2023)

Japan Lifeline Co., Ltd. Provides Dividend Guidance for the Year Ending March 31, 2024

Japan Lifeline Co., Ltd. Announces the Appointment of Nobuo Takahashi as Operating Officer, Associate Executive Manager of CVG Business Unit

Price target increased by 11% to JP¥1,258

New major risk - Revenue and earnings growth

Japan Lifeline Co., Ltd. Announces Management Changes

Japan Lifeline Co., Ltd. to Report Q3, 2024 Results on Feb 02, 2024

Second quarter 2024 earnings released: EPS: JP¥22.31 (vs JP¥22.54 in 2Q 2023)

Price target increased by 13% to JP¥1,280

Now 23% undervalued

Now 21% undervalued

Japan Lifeline Co., Ltd. Announces That It Will Start Selling A New Lineup of Its Proprietary Open Stent Graft Product Frozenix Partial ET from August 2023

Now 23% undervalued

First quarter 2024 earnings released: EPS: JP¥30.02 (vs JP¥24.73 in 1Q 2023)

Japan Lifeline Co., Ltd. to Report Q2, 2024 Results on Nov 06, 2023

Full year 2023 earnings: EPS misses analyst expectations

Japan Lifeline Co., Ltd., Annual General Meeting, Jun 28, 2023

Japan Lifeline Announces Changes in Board of Directors, Effective June 28, 2023

Upcoming dividend of JP¥38.00 per share at 4.1% yield

Japan Lifeline Co., Ltd. Revises Financial Forecast of Consolidated Financial Results for the Year Ending March 31, 2023

Third quarter 2023 earnings released: EPS: JP¥11.15 (vs JP¥24.01 in 3Q 2022)

Now 21% undervalued after recent price drop

Second quarter 2023 earnings released: EPS: JP¥23.64 (vs JP¥23.49 in 2Q 2022)

Second quarter 2023 earnings released: EPS: JP¥23.64 (vs JP¥23.49 in 2Q 2022)

Japan Lifeline Co., Ltd. Provides Year End Dividend Guidance for the Year Ending March 31, 2023

Consensus forecasts updated

Japan Lifeline Co., Ltd. Launches Series of In-House Products for Biliary-Pancreatic Endoscopy

Japan Lifeline Co., Ltd. Announces Executive Changes, Effective October 1, 2022 Respectively

Japan Lifeline Co., Ltd. to Report Q3, 2023 Results on Feb 01, 2023

First quarter 2023 earnings released: EPS: JP¥24.73 (vs JP¥21.17 in 1Q 2022)

Japan Lifeline Co., Ltd. Provides Consolidated Earnings Guidance for Six Months Ending September 30, 2022 and Year Ending March 31, 2023

Japan Lifeline Co., Ltd. to Report Q2, 2023 Results on Nov 02, 2022

Price target decreased to JP¥1,120

Japan Lifeline Co., Ltd. Announces Dividend for Year Ended March 31, 2022, Effective Date Is June 29, 2022

Full year 2022 earnings: EPS in line with expectations, revenues disappoint

Japan Lifeline Co., Ltd., Annual General Meeting, Jun 28, 2022

Consensus EPS estimates fall by 12%

Japan Lifeline Co., Ltd. Appoints Shigeki Kitayama as Operating Officer

Upcoming dividend of JP¥38.00 per share

Third quarter 2022 earnings: EPS misses analyst expectations

Japan Lifeline Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2022

Price target decreased to JP¥1,500

Japan Lifeline Co., Ltd. Provides Earnings Guidance for the Six Months Ending September 30, 2021 and Full Year of Ending March 31, 2022

First quarter 2022 earnings released: EPS JP¥21.17 (vs JP¥10.53 in 1Q 2021)

Metcela Inc. and Japan Lifeline Co., Ltd. Announces Initiation of Phase I Clinical Trial of MTC001 in Patients with Chronic Ischemic Heart Failure

VP, GM of CRM Business Division & Director Osamu Watanabe has left the company

Japan Lifeline Receives Regulatory Approval for HeartLight X3

Japan Lifeline Co., Ltd. Receives Regulatory Approval for Abdominal Stent Graft Alto

Full year 2021 earnings released: EPS JP¥24.90 (vs JP¥96.55 in FY 2020)

Japan Lifeline Co., Ltd. Provides Year End Cash Dividend Guidance for the Year Ending March 31, 2022

Consensus forecasts updated

Upcoming dividend of JP¥49.00 per share

New 90-day low: JP¥1,365

Cardiofocus, Inc. Announces Expanded Partnership with Japan Lifeline Co., Ltd

Third quarter 2021 earnings released: JP¥31.57 loss per share (vs JP¥27.44 profit in 3Q 2020)

Revenue and earnings miss expectations

Analysts update estimates

New 90-day high: JP¥1,633

Japan Lifeline Co., Ltd. Announces Changes in Personnel

New 90-day high: JP¥1,515

Baylis Medical and Japan Lifeline Partner to Introduce Advanced Electrophysiology Solutions into Europe

Japan Lifeline Co., Ltd. Enters into Sales Contract with Baylis Medical Company, Inc. for Sales of EP (Electrophysiological) Catheters Manufactured and Sold by the Company in the European Market

Japan Lifeline Co., Ltd. Announces Activation of HeartLogic Function and Release of its Clinical Use

Japan Lifeline Co., Ltd. to Report Q1, 2021 Results on Aug 05, 2020